Published Studies Examining Long-Term SSEs with Single-Dose RAI
Study | No. of patients | Method of preparation | Study design | First ablation with 131I, median dose range (MBq) | Salivary gland toxicity (%) | Dose-response relationship | Follow-up duration (mo) | Chronic symptoms |
---|---|---|---|---|---|---|---|---|
Solans et al. (11) | 79 | Hypothyroid | Prospective | 925–18,500 (25–500) | 33 | Yes | 36 | 15% at 36 mo |
Hyer et al. (12) | 76 | Hypothyroid | Prospective | 2,960–8,695 (80–235) | 26 | Not reported | 12 | 20% at 12 mo |
Edmonds and Smith (22) | 258 | Hypothyroid | Retrospective | 2,960–8,510 (80–230) | 10 | ? | Unknown | — |
Hoelzer et al. (23) | 2,376 | Hypothyroid | Prospective | 999–11,988 (27–324) | 6.79* | Yes | Unknown | — |
↵* Time since RAI ablation not stated.
Data in parentheses are millicuries.